Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Times Interest Earned (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Times Interest Earned for 6 consecutive years, with -$1064.1 as the latest value for Q4 2025.

  • On a quarterly basis, Times Interest Earned rose 22.26% to -$1064.1 in Q4 2025 year-over-year; TTM through Dec 2025 was -$944.32, a 10.13% increase, with the full-year FY2025 number at -$944.32, up 10.13% from a year prior.
  • Times Interest Earned was -$1064.1 for Q4 2025 at Kymera Therapeutics, down from -$944.08 in the prior quarter.
  • In the past five years, Times Interest Earned ranged from a high of -$371.38 in Q4 2023 to a low of -$1402.7 in Q3 2023.
  • A 5-year average of -$931.65 and a median of -$902.31 in 2022 define the central range for Times Interest Earned.
  • Peak YoY movement for Times Interest Earned: soared 43.28% in 2023, then tumbled 268.55% in 2024.
  • Kymera Therapeutics' Times Interest Earned stood at -$852.76 in 2021, then grew by 23.22% to -$654.76 in 2022, then skyrocketed by 43.28% to -$371.38 in 2023, then crashed by 268.55% to -$1368.7 in 2024, then grew by 22.26% to -$1064.1 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Times Interest Earned are -$1064.1 (Q4 2025), -$944.08 (Q3 2025), and -$782.94 (Q2 2025).